A Clinical Trial to Evaluate Kerecis Oral™ Compared to Autogenous Free Gingival Graft (AFGG) Tissue to Augment Gingival Soft Tissue and Wound Healing

Inclusion Criteria: 1. Age must be at least 18 years but no more than 70 years. 2. There must be at least two non-adjacent teeth in contralateral sides of the same jaw with an insufficient zone (≤ 2mm) of Keratinized gingiva that requires soft tissue grafting. (1-4 teeth may be treated). If adjacent teeth require grafting, only a single chosen tooth at each site will act as the test or control site, all teeth will however get the same treatment). 3. The goal of grafting will not be root coverage. 4. Females must have a documented negative urine pregnancy test if they are of childbearing potential. 5. All subjects must have read, understood and signed an Informed Consent Form (approved by the institutional review board (IRB)). 6. All subjects must be willing and able to follow study instructions and protocols. Exclusion Criteria: 1. Any subject that has class III/IV recession with a shallow vestibule. 2. Any subject that has a vestibule depth of less than 7mm from the base of recession. 3. Any subjects with systemic conditions (i.e., diabetes mellitus, HIV, cancer, bone metabolic diseases) that typically precludes periodontal surgery. 4. Any subjects who are currently taking/received or have taken/received within two months prior to study entry, systemic corticosteroids, immunosupressive agents, radiation therapy, and/or chemotherapy which could compromise wound healing and preclude periodontal surgery. Any subjects taking intramuscular or intravenous bisphosphonates. 5. Any subjects with any acute lesions in the areas intended for surgery/or with a history of aphthous ulcers. 6. Any subjects who currently smoke. 7. Any subject with molar teeth that require treatment at the time of surgery. 8. Any subjects with teeth with Miller Grade =\>2 mobility. 9. Any patients with known hypersensitivity to bovine collagen and/or iodine (shellfish allergy). 10. Any subjects who have received an investigational drug or biological/bioactive treatment within 30 days prior to study enrollment (medical or dental). 11. Any subjects previously treated with any allografts at the target site(s) or immediately adjacent teeth. 12. Any subjects who will not be able to complete the study per protocol.